BUSINESSAug 3 · 11:25 UTCSTAT NEWSAndrew Joseph

STAT+: BioNTech names Guido Oelkers its new CEO

BioNTech appointed Guido Oelkers as its new CEO, replacing Ugur Sahin. Oelkers, a biopharma industry veteran, will lead the company's shift toward oncology and aim for multiple approved medicines by 2030. Sahin and cofounder Özlem Türeci are leaving to launch a new biotech focused on mRNA medicines.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

BioNTechorganizationGuido OelkerspersonSobiorganizationUgur SahinpersonÖzlem TürecipersononcologytopicmRNA medicinestopic

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

BUSINESSMay 6 · 14:42 UTC
COVID pioneer BioNTech: The fall of Germany's pandemic hero
BUSINESSJul 27 · 13:49 UTC
STAT+: Sarepta names Michael Severino, former Tessera CEO, as new chief executive
HEALTHJul 6 · 13:37 UTC
STAT+: Four major biotech updates to catch up on
HEALTHMay 26 · 13:50 UTC
STAT+: Five biotech news updates to stay on top of today
HEALTHMay 28 · 18:48 UTC
STAT+: Biotech veteran Jeremey Levin on why the industry’s future is secure, but American leadership is at risk
HEALTHMay 14 · 13:44 UTC
STAT+: Pharmalittle: We’re reading about upbeat results for a Duchenne drug, Takeda layoffs, and much more